---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-075272"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:57:51.619337+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BiomX reports Q2 net loss $6.0M, cash $15.2M; BX211 shows >40% wound reduction in Phase 2

## Summary
- Cash and restricted cash $15.2M at June 30, 2025; estimated to fund ops into Q1 2026.
- Net loss $6.0M for Q2 2025 vs. income $4.5M in Q2 2024, driven by warrant fair value change.
- BX211 Phase 2: >40% wound size reduction vs placebo in diabetic foot osteomyelitis; registrational study planning underway.
- BX004 Phase 2b in CF successfully initiated dosing; topline results expected Q1 2026.
- Nature Comm. publication: BX004 showed ~500-fold (2.7 log₁₀) bacterial reduction vs placebo with no resistance.

## SEC filing metadata
- accession: 0001213900-25-075272
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390025075272/0001213900-25-075272-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390025075272/ea0253022-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-075272
- JSON: https://secwatch.observer/filing/0001213900-25-075272.json
- Plain text: https://secwatch.observer/filing/0001213900-25-075272.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.